Skip to main content
JEIL PHARMACEUTICAL CO.,LTD logo

JEIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 271980 ISIN · KR7271980005 KO Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 271980

About JEIL PHARMACEUTICAL CO.,LTD

https://www.jeilpharm.co.kr/english/

JEIL PHARMACEUTICAL CO.,LTD. is a company engaged in the development, manufacturing, and distribution of pharmaceutical products. Its portfolio includes both finished drug products and Active Pharmaceutical Ingredients (APIs). The company produces a diverse range of dosage forms, such as solid medicines (tablets and capsules), patches, and injections, with a strategic focus on becoming a leading manufacturer of injection-based medicines. Committed to developing high-value products, the company operates KGMP-certified manufacturing facilities. Research and development activities are central to its operations, driven by its dedicated R&D center.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서 (제 10기 1분기) 2026년 01월 01일 – 2026년 03월 31일,” which translates to a quarterly (interim) report for Q1 2026. It contains full financial statements (summary financials, consolidated and separate financial statements and notes), management’s review and analysis, audit opinion, detailed business overview, capital changes, and other substantive financial data. This aligns exactly with our definition of an Interim/Quarterly Report (IR). It is not merely an announcement or certification; it is the complete report itself. Hence, it should be classified as IR. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-04-30 Korean
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “정기주주총회결과” and contains the detailed results of the annual general shareholders’ meeting, including voting outcomes for each agenda item, director appointments, and other meeting resolutions. This clearly corresponds to a declaration of voting results at a general meeting. Therefore, the correct classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2026-03-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official results of an annual general meeting held on 2026-03-24, detailing the approval votes on financial statements, dividend resolutions, and board appointments, along with voting percentages and resolutions passed. This corresponds to a Declaration of Voting Results (DVA) filing.
2026-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal notification to the Financial Services Commission and Korea Exchange regarding the appointment, reappointment, or dismissal of outside directors, detailing board composition changes (names, terms, prior positions). This clearly fits the definition of a Board/Management Information filing (MANG).
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Jeil Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not a summary or an announcement, fitting the 'Audit Report' (AR) category. FY 2025
2026-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.